RXRX

RECURSION PHARMACEUTICALS, INC.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1601830Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$0.08B

Net Income FY2025

$(0.65B)

EPS (Basic, as reported)

$-1.44

Net Margin FY2025

-863.4%

ROE FY2025

-57.0%

Total Equity

$1.13B

Shares Out

535M

Business description

RECURSION PHARMACEUTICALS, INC. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 2 → 75 +83% CAGR

Fiscal yearFY2019FY2020⚑FY2021⚑FY2022FY2023FY2024⚑FY2025

Revenue241040455975

Cost of revenue—00(48)(43)(45)(71)

Research & development(46)(63)(135)(156)(241)(314)(475)

General & administrative(19)(25)(58)(82)(111)(178)(177)

Total operating expenses(65)(89)(193)(286)(395)(538)(723)

Operating income(62)(85)(183)(246)(350)(479)(648)

Interest expense(1)(1)(3)00(2)(2)

Other income (expense), net1(2)(4)618143

Pre-tax income——(186)(239)(332)(465)(645)

Income tax expense0000(4)(1)0

Net income(62)(87)(186)(239)(328)(464)(645)

EPS — basic($2.87)($3.99)($1.49)($1.36)($1.58)($1.69)($1.44)

EPS — diluted($2.87)($3.99)($1.49)($1.36)($1.58)($1.69)($1.44)

Shares outstanding — basic (M)2222125176208274447

Shares outstanding — diluted (M)2222125176208274447

⚑ Weighted-average shares changed ×5.68 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.41 between FY2021 and FY2022 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.63 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.